CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt.
Ahmed ShawkyHussein SabitMahmoud NazihKhalid BarakaMokhtar El-ZawahryPublished in: Journal of epidemiology and global health (2023)
This study, along with other studies that address genotype variation of clopidogrel-metabolizing enzymes, might pave the way for further understanding of the pharmacogenetic background of CVD-related drugs.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- antiplatelet therapy
- st segment elevation myocardial infarction
- end stage renal disease
- coronary artery disease
- acute myocardial infarction
- st elevation myocardial infarction
- ejection fraction
- newly diagnosed
- coronary artery bypass grafting
- chronic kidney disease
- heart failure
- prognostic factors
- coronary artery bypass
- peritoneal dialysis
- atrial fibrillation
- drug induced